|
|
Blood, 1 January 2005, Vol. 105, No. 1, pp. 131-138.
Prepublished online as a Blood First Edition Paper on August 10, 2004; DOI 10.1182/blood-2004-04-1544.
Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia
Lubica Rauova,
Mortimer Poncz,
Steven E. McKenzie,
Michael P. Reilly,
Gowthami Arepally,
John W. Weisel,
Chandrasekaran Nagaswami,
Douglas B. Cines, and
Bruce S. Sachais
From the Division of Hematology, Children's Hospital of Philadelphia, PA; the Cardeza Foundation for Hematologic Research, Jefferson Medical College, Philadelphia, PA; the Division of Hematology, Duke University Medical Center, Durham, NC; the Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia; and the Department of Cell and Developmental Biology, University of Pennsylvania School of Medicine, Philadelphia.
Heparin-induced thrombocytopenia and thrombosis (HITT) is a severe complication of heparin therapy caused by antibodies to complexes between unfractionated heparin (UFH) and platelet factor 4 (PF4) that form over a narrow molar range of reactants and initiate antibody-induced platelet activation. We observed that UFH and tetrameric PF4 formed ultralarge (> 670 kDa) complexes (ULCs) only over a narrow molar range with an optimal ratio of PF4 to heparin of approximately 1:1. These ULCs were stable and visible by electron microscopy, but they could be dissociated into smaller complexes upon addition of heparin. ULCs formed inefficiently when PF4 was incubated with low-molecular-weight heparin, and none formed with the pentasaccharide fondaparinux sodium. In addition, mutation studies showed that formation of ULCs depended on the presence of PF4 tetramers. The ULCs were more reactive as determined by their capacity to bind to a HITT-like monoclonal antibody and showed greater capacity to promote platelet activation in an antibody- and Fc RIIA-dependent manner than were the smaller complexes. The capacity of PF4 to form ULCs composed of multiple PF4 tetramers arrayed in a lattice with several molecules of UFH may play a fundamental role in autoantibody formation, antibody-dependent platelet activation, and the propensity for thrombosis in patients with HITT.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
New insights in heparin-induced thrombocytopenia
- Michael H. Rosove
Blood 2005 105: 4-5.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
S. Suvarna, B. Espinasse, R. Qi, R. Lubica, M. Poncz, D. B. Cines, M. R. Wiesner, and G. M. Arepally
Determinants of PF4/heparin immunogenicity
Blood,
December 15, 2007;
110(13):
4253 - 4260.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. E. Warkentin, J.-A. I. Sheppard, C. S. Sigouin, T. Kohlmann, P. Eichler, and A. Greinacher
Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia
Blood,
November 1, 2006;
108(9):
2937 - 2941.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Greinacher, M. Gopinadhan, J.-U. Gunther, M. A. Omer-Adam, U. Strobel, T. E. Warkentin, G. Papastavrou, W. Weitschies, and C. A. Helm
Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralization Forms the Antigens Recognized by HIT Antibodies
Arterioscler. Thromb. Vasc. Biol.,
October 1, 2006;
26(10):
2386 - 2393.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. de Maistre, Y. Gruel, and D. Lasne
Diagnosis and management of heparin-induced thrombocytopenia: [Le diagnostic et le traitement de la thrombopenie induite par l'heparine].
Can J Anesth,
June 1, 2006;
53(6_suppl):
S123 - S134.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Rauova, L. Zhai, M. A. Kowalska, G. M. Arepally, D. B. Cines, and M. Poncz
Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications
Blood,
March 15, 2006;
107(6):
2346 - 2353.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. M. Arepally
The immune paradox of fondaparinux
Blood,
December 1, 2005;
106(12):
3686 - 3687.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. E. Warkentin, R. J. Cook, V. J. Marder, J.-A. I. Sheppard, J. C. Moore, B. I. Eriksson, A. Greinacher, and J. G. Kelton
Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin
Blood,
December 1, 2005;
106(12):
3791 - 3796.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Suvarna, L. Rauova, E. K. E. McCracken, C. M. Goss, B. S. Sachais, S. E. McKenzie, M. P. Reilly, M. D. Gunn, D. B. Cines, M. Poncz, et al.
PF4/heparin complexes are T cell-dependent antigens
Blood,
August 1, 2005;
106(3):
929 - 931.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|